Cellular Biomedicine (CBMG) Form 4 Cellular Biomedicine / Chun Kwok Alan Au ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Au Chun Kwok Alan

(Last) (First) (Middle)

C/O CELLULAR BIOMEDICINE GROUP, INC.

9605 MEDICAL CENTER DRIVE, SUITE 100

(Street)

ROCKVILLE MD 20850

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cellular Biomedicine Group, Inc. [ CBMG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/19/2021

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option	$15.62	02/19/2021(1)		D			4,000	11/07/2015	11/07/2024	Common Stock	4,000	(2)	0	D
Non-Qualified Stock Option	$20	02/19/2021(3)		D			5,056	11/08/2016	02/09/2023	Common Stock	5,056	(4)	0	D
Non-Qualified Stock Option	$20	02/19/2021(5)		D			2,060	11/06/2016	03/25/2023	Common Stock	2,060	(4)	0	D
Non-Qualified Stock Option	$13.35	02/19/2021(6)		D			9,789	06/02/2017	12/28/2026	Common Stock	9,789	(2)	0	D
Non-Qualified Stock Option	$10.8	02/19/2021(7)		D			12,056	04/28/2018	04/28/2027	Common Stock	12,056	(2)	0	D
Non-Qualified Stock Option	$19.71	02/19/2021		D			7,213	04/26/2019	05/18/2028	Common Stock	7,213	(2)	0	D
Non-Qualified Stock Option	$17	02/19/2021(8)		D			2,238	04/24/2020	05/15/2029	Common Stock	2,238	(2)	0	D
Non-Qualified Stock Option	$17.89	02/19/2021(9)		D			1,390	04/24/2020	11/11/2029	Common Stock	1,390	(2)	0	D
Non-Qualified Stock Option	$14.68(10)	02/19/2021		D			6,348	04/23/2021(11)	04/25/2030	Common Stock	6,348	(2)	0	D

Explanation of Responses:

1. As previously reported on the Issuer's Form DEF 14A Definitive Proxy Statement filed on March 12, 2018, on November 7, 2014 the Reporting Person was granted an option to purchase up to 4,000 shares of common stock, all of which vested and became fully exercisable on November 7, 2015.

2. Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 11, 2020, by and among Cellular Biomedicine Group, Inc. (the "Company"), CBMG Holdings ("Parent") and CBMG Merger Sub Inc. ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving the Merger as a wholly-owned subsidiary of Parent (the "Merger"). The Merger became effective on February 19, 2021 (the "Closing Date"). Pursuant to the Merger Agreement, at the effective time of the Merger, each stock option was cancelled and exchanged for the right to receive an amount in cash equal to (A) the total number of shares of common stock subject to such stock option multiplied by (B) the excess, if any, of the per share merger consideration of $19.75 over the exercise price of the stock option.

3. As previously reported on the Issuer's Form DEF 14A Definitive Proxy Statement filed on March 12, 2018, on February 9, 2016 the Reporting Person was granted an option to purchase up to 5,056 shares of common stock, all of which vested and became fully exercisable on November 8, 2016.

4. Pursuant to the Merger Agreement, on the Closing Date each stock option with an exercise price greater than the per share merger consideration of $19.75 was cancelled for no consideration or payment.

5. As previously reported on the Issuer's Form DEF 14A Definitive Proxy Statement filed on March 12, 2018, on March 25, 2016 the Reporting Person was granted an option to purchase up to 2,060 shares of common stock, all of which vested and became fully exercisable on November 6, 2016.

6. As previously reported on the Issuer's Form DEF 14A Definitive Proxy Statement filed on March 12, 2018, on December 28, 2016 the Reporting Person was granted an option to purchase up to 9,789 shares of common stock, all of which vested and became fully exercisable on June 2, 2017.

7. As previously reported on the Issuer's Form DEF 14A Definitive Proxy Statement filed on March 12, 2018, on April 28, 2017 the Reporting Person was granted an option to purchase up to 12,056 shares of common stock, all of which vested and became fully exercisable on April 28, 2018.

8. As previously reported on the Issuer's Form DEF 14A Definitive Proxy Statement filed on April 29, 2020, on May 15, 2019 the Reporting Person was granted an option to purchase up to 3,133 shares of common stock, 895 shares of which were forfeited on July 3, 2019 when the Reporting Person elected to change the ratio of his cash and option compensation. The remaining 2,238 stock options vested and became fully exercisable on April 24, 2020.

9. As previously reported on the Issuer's Form DEF 14A Definitive Proxy Statement filed on April 29, 2020, on November 11, 2019 the Reporting Person was granted an option to purchase up to 1,390 shares of common stock, all of which vested and became fully exercisable on April 24, 2020.

10. The exercise price of this option to purchase shares of common stock was previously reported erroneously as $14.65 in the Reporting Person's Form 4 filed on April 28, 2020.

11. In connection with the Merger, unvested options were accelerated and vested in full at the effective time of the Merger.

	/s/ Alan Au	02/19/2021
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.